Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

The Coming Age of Flavonoids in the Treatment of Diabetic Complications.

Caro-Ordieres T, Marín-Royo G, Opazo-Ríos L, Jiménez-Castilla L, Moreno JA, Gómez-Guerrero C, Egido J.

J Clin Med. 2020 Jan 27;9(2). pii: E346. doi: 10.3390/jcm9020346. Review.

2.

Editorial: Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches.

Egea J, González-Rodríguez Á, Gómez-Guerrero C, Moreno JA.

Front Pharmacol. 2019 Oct 4;10:1149. doi: 10.3389/fphar.2019.01149. eCollection 2019. No abstract available.

3.

Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.

Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Kidney Int. 2019 Oct;96(4):995-1004. doi: 10.1016/j.kint.2019.05.014. Epub 2019 May 31.

PMID:
31420192
4.

Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury.

Rubio-Navarro A, Vázquez-Carballo C, Guerrero-Hue M, García-Caballero C, Herencia C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Cannata P, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Michalska P, León R, Ortiz A, Egido J, Moreno JA.

Front Pharmacol. 2019 Jul 3;10:740. doi: 10.3389/fphar.2019.00740. eCollection 2019.

5.

IgA Nephropathy in Elderly Patients.

Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, Calviño J, Castillo L, Cobelo C, Delgado-Mallén P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzmán DA, Heras M, Martín-Reyes G, Martinez A, Olea T, Peña JK, Quintana LF, Rabasco C, López Revuelta K, Rodas L, Rodriguez-Mendiola N, Rodriguez E, San Miguel L, Sanchez de la Nieta MD, Shabaka A, Sierra M, Valera A, Velo M, Verde E, Ballarin J, Noboa O, Moreno JA, Gutiérrez E, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN).

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1183-1192. doi: 10.2215/CJN.13251118. Epub 2019 Jul 16.

PMID:
31311818
6.

Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.

Parada E, Casas AI, Palomino-Antolin A, Gómez-Rangel V, Rubio-Navarro A, Farré-Alins V, Narros-Fernandez P, Guerrero-Hue M, Moreno JA, Rosa JM, Roda JM, Hernández-García BJ, Egea J.

Br J Pharmacol. 2019 Aug;176(15):2764-2779. doi: 10.1111/bph.14703. Epub 2019 Jun 17.

PMID:
31074003
7.

Glomerular Hematuria: Cause or Consequence of Renal Inflammation?

Moreno JA, Sevillano Á, Gutiérrez E, Guerrero-Hue M, Vázquez-Carballo C, Yuste C, Herencia C, García-Caballero C, Praga M, Egido J.

Int J Mol Sci. 2019 May 5;20(9). pii: E2205. doi: 10.3390/ijms20092205. Review.

8.

Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death.

Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, Rubio-Navarro A, Vázquez-Carballo C, Herencia C, Martín-Sanchez D, Farré-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA.

FASEB J. 2019 Aug;33(8):8961-8975. doi: 10.1096/fj.201900077R. Epub 2019 Apr 29.

PMID:
31034781
9.

Targeting inflammation in diabetic nephropathy: a tale of hope.

Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J.

Expert Opin Investig Drugs. 2018 Nov;27(11):917-930. doi: 10.1080/13543784.2018.1538352. Epub 2018 Oct 23. Review.

PMID:
30334635
10.

Subtle skin changes that suggest severe disease.

Moreno JA, Romero, Alvarez A, Abella, Lorenzo D, Grimalt R.

BMJ. 2018 May 18;361:k1336. doi: 10.1136/bmj.k1336. No abstract available.

PMID:
29776908
11.

IgA nephropathy: What patients are at risk of progression to end-stage renal disease and how should they be treated?

Praga M, Caravaca F, Yuste C, Cavero T, Hernández E, Morales E, Mérida E, Moreno JA, Sevillano A, Gutiérrez E.

Nefrologia. 2018 Jul - Aug;38(4):347-352. doi: 10.1016/j.nefro.2018.01.001. Epub 2018 Apr 7. English, Spanish. No abstract available.

12.

Podocytes are new cellular targets of haemoglobin-mediated renal damage.

Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA.

J Pathol. 2018 Mar;244(3):296-310. doi: 10.1002/path.5011. Epub 2018 Jan 10.

PMID:
29205354
13.

Adverse effects of the renal accumulation of haem proteins. Novel therapeutic approaches.

Guerrero-Hue M, Rubio-Navarro A, Sevillano Á, Yuste C, Gutiérrez E, Palomino-Antolín A, Román E, Praga M, Egido J, Moreno JA.

Nefrologia. 2018 Jan - Feb;38(1):13-26. doi: 10.1016/j.nefro.2017.05.009. Epub 2017 Jun 28. Review. English, Spanish.

14.

Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

Sevillano AM, Gutiérrez E, Yuste C, Cavero T, Mérida E, Rodríguez P, García A, Morales E, Fernández C, Martínez MA, Moreno JA, Praga M.

J Am Soc Nephrol. 2017 Oct;28(10):3089-3099. doi: 10.1681/ASN.2017010108. Epub 2017 Jun 7.

15.

2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.

González N, Prieto I, Del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J, García-Foncillas J, Ortiz A; DiabetesCancerConnect Consortium.

Oncotarget. 2017 Mar 14;8(11):18456-18485. doi: 10.18632/oncotarget.14472. Review.

16.

Phenotypic Characterization of Macrophages from Rat Kidney by Flow Cytometry.

Rubio-Navarro A, Guerrero-Hue M, Martín-Fernandez B, Cortegano I, Olivares-Alvaro E, de Las Heras N, Alía M, de Andrés B, Gaspar ML, Egido J, Moreno JA.

J Vis Exp. 2016 Oct 18;(116). doi: 10.3791/54599.

17.

Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms.

Ruiz-Andres O, Sanchez-Niño MD, Moreno JA, Ruiz-Ortega M, Ramos AM, Sanz AB, Ortiz A.

Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1329-F1340. doi: 10.1152/ajprenal.00487.2016. Epub 2016 Oct 19. Review.

18.

CD163-Macrophages Are Involved in Rhabdomyolysis-Induced Kidney Injury and May Be Detected by MRI with Targeted Gold-Coated Iron Oxide Nanoparticles.

Rubio-Navarro A, Carril M, Padro D, Guerrero-Hue M, Tarín C, Samaniego R, Cannata P, Cano A, Villalobos JM, Sevillano ÁM, Yuste C, Gutiérrez E, Praga M, Egido J, Moreno JA.

Theranostics. 2016 Apr 21;6(6):896-914. doi: 10.7150/thno.14915. eCollection 2016.

19.

Haematuria on the Spanish Registry of Glomerulonephritis.

Yuste C, Rivera F, Moreno JA, López-Gómez JM.

Sci Rep. 2016 Jan 28;6:19732. doi: 10.1038/srep19732.

20.

Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.

Martín-Fernández B, Rubio-Navarro A, Cortegano I, Ballesteros S, Alía M, Cannata-Ortiz P, Olivares-Álvaro E, Egido J, de Andrés B, Gaspar ML, de Las Heras N, Lahera V, Moreno JA.

PLoS One. 2016 Jan 5;11(1):e0145946. doi: 10.1371/journal.pone.0145946. eCollection 2016.

Supplemental Content

Loading ...
Support Center